{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:12:40Z","timestamp":1783609960129,"version":"3.55.0"},"reference-count":57,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG 4544A1"],"award-info":[{"award-number":["RG 4544A1"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>After decades of development, inhibitors targeting cyclic nucleotide phosphodiesterases (PDEs) expressed in leukocytes have entered clinical practice for the treatment of inflammatory disorders, with three PDE4 inhibitors being in clinical use as therapeutics for psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease and atopic dermatitis. In contrast, the PDE8 family that is upregulated in pro-inflammatory T cells is a largely unexplored therapeutic target. We have previously demonstrated a role for the PDE8A-Raf-1 kinase complex in the regulation of myelin oligodendrocyte glycoprotein peptide 35\u201355 (MOG35\u201355) activated CD4+ effector T cell adhesion and locomotion by a mechanism that differs from PDE4 activity. In this study, we explored the in vivo treatment of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis (MS) induced in mice immunized with MOG using the PDE8-selective inhibitor PF-04957325. For treatment in vivo, mice with EAE were either subcutaneously (s.c.) injected three times daily (10 mg\/kg\/dose), or were implanted subcutaneously with Alzet mini-osmotic pumps to deliver the PDE8 inhibitor (15.5 mg\/kg\/day). The mice were scored daily for clinical signs of paresis and paralysis which were characteristic of EAE. We observed the suppression of the clinical signs of EAE and a reduction of inflammatory lesion formation in the CNS by histopathological analysis through the determination of the numbers of mononuclear cells isolated from the spinal cord of mice with EAE. The PDE8 inhibitor treatment reduces the accumulation of both encephalitogenic Th1 and Th17 T cells in the CNS. Our study demonstrates the efficacy of targeting PDE8 as a treatment of autoimmune inflammation in vivo by reducing the inflammatory lesion load.<\/jats:p>","DOI":"10.3390\/cells11040660","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T20:26:42Z","timestamp":1644870402000},"page":"660","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)"],"prefix":"10.3390","volume":"11","author":[{"given":"Chaitali P.","family":"Basole","sequence":"first","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca K.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Lamothe","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Billis","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"},{"name":"Department of Cell Biology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5540-182X","authenticated-orcid":false,"given":"Mai","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda G.","family":"Vang","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-1478","authenticated-orcid":false,"given":"Stefan","family":"Brocke","sequence":"additional","affiliation":[{"name":"Department of Immunology, UConn Health, Farmington, CT 06030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1126\/science.184.4132.19","article-title":"Modulation of Inflammation and Immunity by Cyclic AMP","volume":"184","author":"Bourne","year":"1974","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1126\/science.208147","article-title":"Rise and Fall of Cyclic AMP Required for Onset of Lymphocyte DNA Synthesis","volume":"201","author":"Wang","year":"1978","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/j.1742-4658.2009.06926.x","article-title":"Compartmentalized signalling: Spatial regulation of cAMP by the action of compartmentalized phosphodiesterases","volume":"276","author":"Baillie","year":"2009","journal-title":"FEBS J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/BJ20051368","article-title":"Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies","volume":"393","author":"Lerner","year":"2006","journal-title":"Biochem. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast\u2014A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm. Pharm. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrrheum.2014.77","article-title":"Spondyloarthropathies: Apremilast: Welcome advance in treatment of psoriatic arthritis","volume":"10","author":"FitzGerald","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40257-019-00450-w","article-title":"Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups","volume":"20","author":"Callender","year":"2019","journal-title":"Am. J. Clin. Derm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/pharmrev.120.000273","article-title":"The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors","volume":"73","author":"Paes","year":"2021","journal-title":"Pharm. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3389\/fimmu.2019.01727","article-title":"Targeting Phosphodiesterases-Towards a Tailor-Made Approach in Multiple Sclerosis Treatment","volume":"10","author":"Schepers","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1165\/rcmb.2017-0294OC","article-title":"PDE8 is Expressed in Human Airway Smooth Muscle and Selectively Regulates cAMP Signaling by beta2AR-AC6","volume":"8","author":"Johnstone","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cellsig.2017.08.007","article-title":"PDE8 controls CD4(+) T cell motility through the PDE8A-Raf-1 kinase signaling complex","volume":"40","author":"Basole","year":"2017","journal-title":"Cell. Signal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2016.00259","article-title":"Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation","volume":"7","author":"Vang","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_15","first-page":"E5685","article-title":"SCAP\/SREBP pathway is required for the full steroidogenic response to cyclic AMP","volume":"113","author":"Golkowski","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-015-3445-9","article-title":"Inhibition of breast cancer cell migration by activation of cAMP signaling","volume":"152","author":"Dong","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1073\/pnas.1303920110","article-title":"PDE8A runs interference to limit PKA inhibition of Raf-1","volume":"110","author":"Maurice","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1124\/mol.110.069104","article-title":"The high affinity cAMP-specific phosphodiesterase 8B (PDE8B) controls steroidogenesis in the mouse adrenal gland","volume":"79","author":"Tsai","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E1533","DOI":"10.1073\/pnas.1303004110","article-title":"Phosphodiesterase-8A binds to and regulates Raf-1 kinase","volume":"110","author":"Brown","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1016\/j.bmcl.2011.03.022","article-title":"1,5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability","volume":"21","author":"DeNinno","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vang, A.G., Ben-Sasson, S.Z., Dong, H., Kream, B., DeNinno, M.P., Claffey, M.M., Housley, W., Clark, R.B., Epstein, P.M., and Brocke, S. (2010). PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012011"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2009.09.001","article-title":"Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells","volume":"79","author":"Dong","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbrc.2006.04.143","article-title":"Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes","volume":"345","author":"Dong","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1073\/pnas.101131098","article-title":"T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3","volume":"98","author":"Glavas","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8991","DOI":"10.1073\/pnas.95.15.8991","article-title":"Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase","volume":"95","author":"Soderling","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1006\/bbrc.1998.8684","article-title":"Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase","volume":"246","author":"Fisher","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12760","DOI":"10.1021\/bi801487x","article-title":"Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity","volume":"47","author":"Wang","year":"2008","journal-title":"Biochemistry"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Demirbas, D., Wyman, A.R., Shimizu-Albergine, M., Cakici, O., Beavo, J.A., and Hoffman, C.S. (2013). A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071279"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1042\/BJ20130064","article-title":"Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM\/ICER: A potential role for Epac","volume":"456","author":"Vang","year":"2013","journal-title":"Biochem. J."},{"key":"ref_30","first-page":"237","article-title":"ERAP1 and PDE8A Are Downregulated in Cattle Protected against Bovine Tuberculosis","volume":"27","author":"Blanco","year":"2017","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41398-018-0331-3","article-title":"Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents","volume":"9","author":"Chimienti","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2567.2008.02850.x","article-title":"Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes","volume":"125","author":"Orlowski","year":"2008","journal-title":"Immunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/art.40040","article-title":"Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sjogren\u2019s Syndrome According to Ancestry","volume":"69","author":"Taylor","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0898-6568(02)00146-8","article-title":"Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans","volume":"15","author":"Gamanuma","year":"2003","journal-title":"Cell. Signal."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.4049\/jimmunol.178.7.4632","article-title":"TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26","volume":"178","author":"Preller","year":"2007","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.iy.08.040190.003051","article-title":"The T lymphocyte in experimental allergic encephalomyelitis","volume":"8","author":"Zamvil","year":"1990","journal-title":"Annu. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.it.2005.08.014","article-title":"Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis","volume":"26","author":"Steinman","year":"2005","journal-title":"Trends Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrd1752","article-title":"Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab","volume":"4","author":"Steinman","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against \u03b14\u03b2l integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1073\/pnas.96.12.6896","article-title":"Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment","volume":"96","author":"Brocke","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/1352458509345903","article-title":"Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis","volume":"15","author":"Bielekova","year":"2009","journal-title":"Mult. Scler. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.bmcl.2012.09.028","article-title":"Future directions in phosphodiesterase drug discovery","volume":"22","author":"DeNinno","year":"2012","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.imbio.2011.07.001","article-title":"Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions","volume":"216","author":"Biton","year":"2011","journal-title":"Immunobiology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2005.08.020","article-title":"Statistical analysis of data from studies on experimental autoimmune encephalomyelitis","volume":"170","author":"Fleming","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1084\/jem.20050308","article-title":"Tim-2 regulates T helper type 2 responses and autoimmunity","volume":"202","author":"Chakravarti","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.2353\/ajpath.2009.090544","article-title":"Unique lipids from a common human bacterium represent a new class of Toll-like receptor 2 ligands capable of enhancing autoimmunity","volume":"175","author":"Nichols","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_47","first-page":"303","article-title":"Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts","volume":"16","author":"Epstein","year":"1984","journal-title":"Adv. Cycl. Nucleotide Protein Phosphorylation Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-642-17969-3_3","article-title":"Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: Impact of human pharmacokinetics","volume":"204","author":"Tenor","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.164.2.1117","article-title":"Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases","volume":"164","author":"Bielekova","year":"2000","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1517\/13543776.2014.968127","article-title":"cAMP-specific phosphodiesterase inhibitors: Promising drugs for inflammatory and neurological diseases","volume":"24","author":"Martinez","year":"2014","journal-title":"Expert Opin. Ther. Patents"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.201207175","article-title":"The discovery of natalizumab, a potent therapeutic for multiple sclerosis","volume":"199","author":"Steinman","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/978-3-642-17969-3_15","article-title":"Phosphodiesterases as targets for modulating T-cell responses","volume":"204","author":"Bjorgo","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneurol.2010.161","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?","volume":"67","author":"Warnke","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1742-2094-10-89","article-title":"Reduction of microglial activity in a model of multiple sclerosis by dipyridamole","volume":"10","author":"Sloka","year":"2013","journal-title":"J. Neuroinflamm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJMoa1803583","article-title":"Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis","volume":"379","author":"Fox","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1080\/13543784.2016.1221924","article-title":"Ibudilast for the treatment of multiple sclerosis","volume":"25","author":"Goodman","year":"2016","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/660\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:19:38Z","timestamp":1760134778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/4\/660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cells11040660"],"URL":"https:\/\/doi.org\/10.3390\/cells11040660","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}